COMMUNIQUÉS West-GlobeNewswire

Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
06/10/2026
Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa. El [...]
Transactions in connection with share buy-back program
06/10/2026
Company announcement no. 38 - 26 06 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
06/10/2026
Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l’innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata [...]
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
06/10/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will [...]
MediciNova to Participate in the Maxim Growth Summit
06/10/2026
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
06/10/2026
First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability. Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer [...]
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
06/10/2026
Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use [...]
Nox Peptides Announces Launch of GHK-Cu and Wolverine Stack for Canadian Research Market
06/10/2026
TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nox Peptides today announced the launch of two research-focused peptide products, GHK-Cu and the Wolverine Stack , expanding its product offering for Canadian laboratories, [...]
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
06/10/2026
CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) , and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Peptides Canada Operated by Growth Guys Announces Launch of Domestic Research Peptide Supply Platform
06/10/2026
TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Peptides Canada , operated by Growth Guys, today announced the launch of its Canadian research-peptide supply platform , providing a domestic online source for peptide [...]
Nox Peptides Announces Expanded Research Focus on BPC-157 as Canadian Peptide Research Supply Demand Grows
06/10/2026
Toronto, ON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nox Peptides today announced an expanded focus on providing information and access to research peptide supplies for Canadian laboratories, academic researchers and [...]
Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire »
06/10/2026
Mise en ligne du document «Q3 2026 aide-mémoire » Paris, France – 6 octobre 2026 . Sanofi annonce la mise en ligne de son « Q3 2026 aide-mémoire » sur la page « Investisseurs » de sanofi.com. Résultats du troisième [...]
Press Release : Availability of the aide-mémoire for Q3 2026 results
06/10/2026
Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026 . Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter [...]
Kylo Peptides Review Brings Transparency to the Research Peptide Market
06/10/2026
Review highlights testing documentation, lot-specific COAs, independent laboratory analysis, and supplier information to help researchers evaluate research peptide sources. Sheridan, Wyoming, Oct. 06, 2026 (GLOBE [...]
Bulk Peptides: Kylo Peptides Launches Bulk Research Program for High-Volume Laboratories
06/10/2026
Sheridan, Wyoming, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ] has introduced a research program that supplies bulk peptides to laboratories with higher-volume peptide requirements. It [...]
Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
06/10/2026
ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation (“Orion Pharma”) and Qilu Pharma [...]
One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event
06/10/2026
First clinical data for CPV-104 in patients, including interim safety, tolerability and pharmacokinetics, accepted as a late-breaking poster Expert panel to join One04 management in a virtual key opinion leader (KOL) [...]
RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
06/10/2026
Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. Financing will [...]
Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program
06/10/2026
Financing will be used to advance Rewind's lead oral program designed to promote remyelination and restore neurological function Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional [...]

Pages